BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 17961335)

  • 1. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
    Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.
    Kim CK; Park BK; Choi JY; Kim BG; Han H
    J Comput Assist Tomogr; 2007; 31(6):868-75. PubMed ID: 18043348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT.
    Bristow RE; del Carmen MG; Pannu HK; Cohade C; Zahurak ML; Fishman EK; Wahl RL; Montz FJ
    Gynecol Oncol; 2003 Sep; 90(3):519-28. PubMed ID: 13678719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer.
    Murakami M; Miyamoto T; Iida T; Tsukada H; Watanabe M; Shida M; Maeda H; Nasu S; Yasuda S; Yasuda M; Ide M
    Int J Gynecol Cancer; 2006; 16 Suppl 1():99-107. PubMed ID: 16515575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
    Bristow RE; Giuntoli RL; Pannu HK; Schulick RD; Fishman EK; Wahl RL
    Gynecol Oncol; 2005 Nov; 99(2):294-300. PubMed ID: 16051330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT.
    Balestreri L; Bison L; Sorio R; Morra A; Campagnutta E; Morassut S
    Radiol Med; 2002; 104(5-6):426-36. PubMed ID: 12589264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
    Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):480-6. PubMed ID: 17089122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of PET/CT in the management of recurrent ovarian cancer.
    Simcock B; Neesham D; Quinn M; Drummond E; Milner A; Hicks RJ
    Gynecol Oncol; 2006 Oct; 103(1):271-6. PubMed ID: 16626793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review.
    Makhija S; Howden N; Edwards R; Kelley J; Townsend DW; Meltzer CC
    Gynecol Oncol; 2002 Apr; 85(1):53-8. PubMed ID: 11925120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer.
    Lenhard SM; Burges A; Johnson TR; Kirschenhofer A; Bruns C; Linke R; Friese K
    Eur J Obstet Gynecol Reprod Biol; 2008 Oct; 140(2):263-8. PubMed ID: 18614272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
    Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
    Takekuma M; Maeda M; Ozawa T; Yasumi K; Torizuka T
    Int J Clin Oncol; 2005 Jun; 10(3):177-81. PubMed ID: 15990965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings.
    Sironi S; Messa C; Mangili G; Zangheri B; Aletti G; Garavaglia E; Vigano R; Picchio M; Taccagni G; Maschio AD; Fazio F
    Radiology; 2004 Nov; 233(2):433-40. PubMed ID: 15516617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
    García Velloso MJ; Boán García JF; Villar Luque LM; Aramendía Beitia JM; López García G; Richter Echeverría JA
    Rev Esp Med Nucl; 2003; 22(4):217-23. PubMed ID: 12846945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis.
    Gu P; Pan LL; Wu SQ; Sun L; Huang G
    Eur J Radiol; 2009 Jul; 71(1):164-74. PubMed ID: 18378417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature.
    Gadducci A; Cosio S; Zola P; Landoni F; Maggino T; Sartori E
    Int J Gynecol Cancer; 2007; 17(1):21-31. PubMed ID: 17291227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.